APA (7th ed.) Citation

P, T., S, S., VK, G., P, P., G, S., T, D., & D, S. (2025). Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2- advanced breast cancer: A Medicare perspective. Journal of medical economics, 28(1), 2125. https://doi.org/10.1080/13696998.2025.2594951

Chicago Style (17th ed.) Citation

P, Tarantino, Sammons S, Gadi VK, Pathak P, Sopher G, Delea T, and Stellato D. "Cost-effectiveness Analysis of Ribociclib Versus Abemaciclib as First-line Treatments for Postmenopausal Women with HR+/HER2- Advanced Breast Cancer: A Medicare Perspective." Journal of Medical Economics 28, no. 1 (2025): 2125. https://doi.org/10.1080/13696998.2025.2594951.

MLA (9th ed.) Citation

P, Tarantino, et al. "Cost-effectiveness Analysis of Ribociclib Versus Abemaciclib as First-line Treatments for Postmenopausal Women with HR+/HER2- Advanced Breast Cancer: A Medicare Perspective." Journal of Medical Economics, vol. 28, no. 1, 2025, p. 2125, https://doi.org/10.1080/13696998.2025.2594951.